Stephanie Grosse

Title: Stephanie Grosse: Pioneer in Immunotherapy Innovation

Introduction:

Stephanie Grosse, a resident of Saint-Cyr-sur-Morin in France, has made significant contributions to the field of immunotherapy through her groundbreaking inventions and patents. As a key member of Cellectis, a renowned biotechnology company, Stephanie's work focuses on engineering allogeneic and immunosuppressive resistant T cells for adoptive immunotherapy strategies. Her expertise has opened new avenues for cancer and viral infection treatments, making her a notable figure in the world of medical innovation.

Latest Patents:

Stephanie Grosse has an impressive portfolio of nine patents, which play a crucial role in advancing the field of immunotherapy. Among her most recent patents are two ground-breaking methods that have potential for revolutionizing the treatment landscape.

1. Methods for Engineering Allogeneic and Immunosuppressive Resistant T Cell for Immunotherapy:

This patent introduces a methodology for modifying T-cells by inactivating genes encoding targets for immunosuppressive agents, as well as T-cell receptors. By employing specific rare-cutting endonucleases, such as TALE-nucleases, and polynucleotides encoding these polypeptides, the invention selectively targets significant genes in T-cells. This breakthrough paves the way for more accessible and standardized adoptive immunotherapy strategies in combating cancer and viral infections.

2. Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells:

This patent addresses expanding deficient T-cells by expressing pTalpha or functional variants, thus restoring the functional CD3 complex. The method involves using pTalpha or its functional counterparts, along with polynucleotides encoding these peptides, for expanding TCRalpha deficient T-cells. By utilizing specific rare-cutting endonucleases, preferably TALE-nucleases, this invention enhances the efficiency of immunotherapy using primary T-cells from donors. The introduction of Chimeric Antigen Receptor (CAR), specifically multi-chain CAR, further amplifies the targeting of malignant or infected cells. This innovation offers promising opportunities for affordable and standardized adoptive immunotherapy in treating cancer and viral infections.

Career Highlights:

Stephanie Grosse's journey as an innovator and inventor has centered around Cellectis, a leading biotechnology company. Her expertise and relentless pursuit of advancements in immunotherapy have earned her recognition within the industry. Stephanie's work has positioned Cellectis as a leading contributor to the development of novel immunotherapeutic strategies.

Collaborations:

Collaboration is a key aspect of Stephanie Grosse's career, as she has worked closely with esteemed colleagues such as Roman Galetto and Agnes Gouble. These collaborations have undoubtedly contributed to the success of her patents and innovative solutions. Stephanie's ability to bring together multiple perspectives has been integral to her achievements in the field of immunotherapy.

Conclusion:

Stephanie Grosse's contributions to the field of immunotherapy, particularly in engineering allogeneic and immunosuppressive resistant T cells, have greatly advanced the field. With her groundbreaking patents, Stephanie has paved the way for more standardized and affordable adoptive immunotherapy strategies in the treatment of cancer and viral infections. Her collaborations and dedication to innovation have earned her recognition within the industry. Stephanie Grosse's work continues to inspire and drive progress in the realm of medical innovation.